Jasper Bos

M Ventures
Gustav Mahlerplein 102
Toyo lto Building, 20th Floor
1082 MA Amsterdam
The Netherlands

Jasper Bos joined Merck KGaA, Darmstadt, Germany previous biopharma fund of M Ventures in 2009 and transitioned to Senior Vice President and Managing Director of M Ventures in 2019. At M Ventures, Jasper Bos supported (amongst others) the early successful investments and exits in ObsEva (NASDAQ), EpiTherapeutics (sale to Gilead), and was an initiator of Prexton Therapeutics, which was acquired early 2018 by Lundbeck for close to US1.1bn, Calypso Biotech, Inthera, Metabomed and Asceneuron. He holds a PhD in Pharmacy from the University of Groningen, the Netherlands, and has previously worked in private equity and at the Netherlands Vaccine Institute. Jasper published over 35 articles on health economics, vaccines and mathematical modelling.

Portfolio Companies

more about
Calypso Biotech
more about
Galecto Biotech
more about
Metabomed LTD
more about